Psoriatic Arthritis

The Pharmacy Times® Psoriatic Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
Bimekizumab Shows Improvement in Psoriatic Arthritis Across Joint, Skin Manifestations
Phase 2b study results show durable responses rates and symptom improvement in patients with psoriatic arthritis.
[[thumbnail_alt_text]]
Updated Secukinumab Label to Include Evidence for Treatment of Psoriatic Arthritis
The updated label includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.
[[thumbnail_alt_text]]
FDA OKs Secukinumab Label Update for Psoriatic Arthritis
The label update includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.
[[thumbnail_alt_text]]
AbbVie Seeks Approval for Moderate to Severe Plaque Psoriasis Drug
Risankizumab shows promise as an important treatment option for people living with plaque psoriasis.
[[thumbnail_alt_text]]
How Will the Biosimilar Market Change in 2018?
Ron Lanton III, Esq, President, True North Political Solutions, makes predictions about how dealings with biosimilars may change in 2018.
[[thumbnail_alt_text]]
Tofacitinib Approved for Active Psoriatic Arthritis
Tofacitinib (Xeljanz/Xeljanz XR) improves disease severity for patients with psoriatic arthritis.
[[thumbnail_alt_text]]
Secukinumab Demonstrates Efficacy in Nail, Palmoplantar Psoriasis
Up to 90% of patients with psoriasis develop plaque on their nails, palms of the hands, and soles of the feet.
[[thumbnail_alt_text]]
Complex Link Between Atopic Dermatitis With Asthma, Food Allergies
Hay fever and asthma are dependent on allergens that stimulate the immunoglobulin E pathway, which is not the case with atopic dermatitis.
[[thumbnail_alt_text]]
Taltz Gets FDA Approval for Psoriatic Arthritis
Ixekizumab found to provide significant improvement in joint symptoms for patients not previously treated with a biologic disease-modifying antirheumatic drug.
[[thumbnail_alt_text]]
Cosentyx Shows Promise Treating Nail, Palmoplantar Psoriasis
Patients with moderate-to-severe nail psoriasis treated with secukinumab experienced significant improvement in the Nail Psoriasis Severity Index.
[[thumbnail_alt_text]]
Cosentyx May Prevent Joint Structural Damage in Psoriatic Arthritis Patients
Secukinumab (Cosentyx) treatment observed to improve the signs and symptoms of psoriatic arthritis.
[[thumbnail_alt_text]]
Approval Sought for Plaque Psoriasis Drug
New Drug Applications filed for halobetasol propionate and tazarotene lotion, a topical treatment for plaque psoriasis.

The Pharmacy Times® Psoriatic Arthritis resource center serves as a hub for all clinical news and articles related to this form of arthritis affecting people who have the dermatological condition psoriasis. The coverage includes updates from the floor of all the biggest societal conferences and annual meetings, as well as video interviews of the leading experts and key opinion leaders from the space.

Among the content in this resource center is breaking news coverage of newly approved drugs by the US Food and Drug Administration, and key takeaways from the latest novel therapies in clinical trials.